Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C

Hepatology Research

Volumn 40, Issue 9, 2010, Pages 911-922

  Fukushima, Nobuyoshi ^a,b   Kuromatsu, Ryoko ^a   Arinaga Hino, Teruko ^a   Ando, Eiji ^a   Takata, Akio ^a   Sumie, Shuji ^a   Nakano, Masahito ^a   Kawaguchi, Takumi ^a   Ide, Tatsuya ^a   Torimura, Takuji ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Adipocytokine; Adiponectin; Hepatocellular carcinoma; Insulin resistance; Leptin; Sustained virological response

Indexed keywords

ADIPOCYTOKINE; INSULIN; INTERFERON; LEPTIN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HISTOLOGY; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 77956151013     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00699.x     Document Type: Article

References (65)

1. Wong F, Choi T. Primary liver cancer. Asian experience. Surgery of Liver and Biliary Tract 1988, 1135-51. Blumgart LH, ed., London, Churchill-Livingstone
2. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002, 62(1):8-17. Suppl
3. Hiramatsu N, Hayashi N, Kasahara A. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 1995, 22:135-42.
4. Yoshida H, Shiratori Y, Moriyama M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999, 131:174-81.
5. Kasahara A, Hayashi N, Mochizuki K. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998, 27:1394-402.
6. Makiyama A, Itoh Y, Kasahara A. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004, 101:1616-22.
7. Iwasaki Y, Takaguchi K, Ikeda H. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. Liver Int 2004, 24:603-10.
8. Kobayashi S, Takeda T, Enomoto M. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int 2007, 27:186-91.
9. Tokita H, Fukui H, Tanaka A. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 2005, 20:752-8.
10. Tanaka A, Uegaki S, Kurihara H. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007, 13:5180-7.
11. Ikeda M, Fujiyama S, Tanaka M. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005, 40:148-56.
12. Mason AL, Lau JY, Hoang N. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 29:328-33.
13. Shintani Y, Fujie H, Miyoshi H. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-8.
14. Kawaguchi T, Ide T, Taniguchi E. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007, 102:570-6.
15. Adami HO, Chow WH, Nyren O. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996, 88:1472-7.
16. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-8.
17. Gruppuso PA, Boylan JM, Bienieki TC, Curran TR. Evidence for a direct hepatotrophic role for insulin in the fetal rat: implications for the impaired hepatic growth seen in fetal growth retardation. Endocrinology 1994, 134:769-75.
18. Saito K, Inoue S, Saito T. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002, 51:100-4.
19. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-38.
20. Chen CL, Yang HI, Yang WS. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008, 135:111-21.
21. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987, 36:54-9.
22. Ahima RS. Central actions of adipocyte hormones. Trends Endocrinol Metab 2005, 16:307-13.
23. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003, 100:7265-70.
24. Yamauchi T, Kamon J, Waki H. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001, 276:41245-54.
25. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003, 148:293-300.
26. Yamauchi T, Kamon J, Ito Y. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-9.
27. Sierra-Honigmann MR, Nath AK, Murakami C. Biological action of leptin as an angiogenic factor. Science 1998, 281:1683-6.
28. Janeckova R. The role of leptin in human physiology and pathophysiology. Physiol Res 2001, 50:443-59.
29. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005, 97:1688-94.
30. Miyoshi Y, Funahashi T, Kihara S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003, 9:5699-704.
31. Adachi Y, Takeuchi T, Sonobe H, Ohtsuki Y. An adiponectin receptor, T-cadherin, was selectively expressed in intratumoral capillary endothelial cells in hepatocellular carcinoma: possible cross talk between T-cadherin and FGF-2 pathways. Virchows Arch 2006, 448:311-18.
32. Chang S, Hursting SD, Contois JH. Leptin and prostate cancer. Prostate 2001, 46:62-7.
33. Wang SN, Yeh YT, Yang SF, Chai CY, Lee KT. Potential role of leptin expression in hepatocellular carcinoma. J Clin Pathol 2006, 59:930-4.
34. Chen C, Chang YC, Liu CL, Liu TP, Chang KJ, Guo IC. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr Relat Cancer 2007, 14:513-29.
35. Zhou J, Lei W, Shen L, Luo HS, Shen ZX. Primary study of leptin and human hepatocellular carcinoma in vitro. World J Gastroenterol 2008, 14:2900-4.
36. Ribatti D, Belloni AS, Nico B, Di Comite M, Crivellato E, Vacca A. Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma. Peptides 2008, 29:1596-602.
37. Sizmann D, Boeck C, Boelter J. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007, 38:326-33.
38. Hagiwara H, Hayashi N, Mita E. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993, 104:877-83.
39. Yuki N, Hayashi N, Kasahara A. Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C. J Hepatol 1995, 22:457-63.
40. Shiratori Y, Kato N, Yokosuka O. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997, 113:558-66.
41. Okamoto H, Tokita H, Sakamoto M. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993, 74(Pt 11):2385-90.
42. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003, 14:561-6.
43. Pajvani UB, Du X, Combs TP. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003, 278:9073-85.
44. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19:1513-20.
45. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-74.
46. Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol 2002, 9:37-51.
47. General Rules for the Clinical and Pathological Study of Primary Liver Cancer 2003, Liver Cancer Study Group of Japan, ed., 2nd, English, edn., Tokyo, Kanehara
48. Sobin L, Witteking C. International Union against Cancer. Union TMN Classification of Malignant Tumors 1997, eds., 5th, edn., New York, John Wiley & Sons, Inc.
49. Pugh RN, Murray-Lyon IM, Dawson JL. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-9.
50. Boulton TG, Nye SH, Robbins DJ. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991, 65:663-75.
51. Hui JM, Sud A, Farrell GC. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected. Gastroenterology 2003, 125:1695-704.
52. Okanoue T, Itoh Y, Minami M. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999, 30:653-9.
53. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999, 30:783-7.
54. Weyer C, Funahashi T, Tanaka S. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-5.
55. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008, 15:91-101.
56. Arita Y, Kihara S, Ouchi N. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
57. Considine RV, Sinha MK, Heiman ML. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 334:292-5.
58. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999, 401:73-6.
59. Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995, 1:1311-14.
60. Dubuisson L, Desmouliere A, Decourt B. Inhibition of rat liver fibrogenesis through noradrenergic antagonism. Hepatology 2002, 35:325-31.
61. Zografos TA, Rigopoulou EI, Liaskos C. Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. J Hepatol 2006, 44:848-55.
62. Lo Iacono O, Venezia G, Petta S. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007, 25:1181-91.
63. Lu JY, Chuang LM, Yang WS. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int 2005, 25:752-9.
64. Pessione F, Ramond MJ, Njapoum C. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001, 34:121-5.
65. Austin H. The role of tobacco use and alcohol consumption in the etiology of hepatocellular carcinoma. Etiology, Pathology and Treatment of Hepatocellular Carcinoma in North America 2007, 57-70. Tabor EDiBisceglie APurcell R. In, eds., Vol. 13, The Woodlands, TX, Portfolio Publishing Company